healthcare sector in india monthly update november 2012

7/29/2019 Healthcare Sector in India Monthly Update November 2012

http://slidepdf.com/reader/full/healthcare-sector-in-india-monthly-update-november-2012 1/12

Healthcare Sector in India

Monthly Update

November 2012



Top Story

Ireland India tie up for biomaterial research

Ireland‐India relations are being strengthened by The Network of Excellence for FunctionalBiomaterials (NFB) at NUI Galway for the purpose of research in biosciences. The

biomaterials research group of NFB will be tying up with NFB the Materials Research Centre

at the Indian Institute of Science, Bangalore; the Indian Institute of Technology in Kanpur;

the Indian Institute of Technology in New Delhi and the Sree Chitra Tirunal Institute of

edical Science and Technology in Trivandrum for increasing co‐operation andM

communication within the international community of public health research.

NFB focuses on carrying out research on biomaterials to develop technologies with clinical

applications in the fields of orthopedics, soft‐tissue healing and neural and cardiovascular

regeneration. The tie up will facilitate translational activities and commercial exploitation of

developing technologies.

News Update

General

Advanced CT scanner installed in Kolkata diagnostic lab

Kolkata based Pulse Diagnostics Pvt. Ltd. has recently installed a highly advanced Computed

Tomography (CT) scanner that reduces a patient’s exposure to the harmful radiation. The

Wipro GE manufactured device is the 1st of its kind equipment to be installed in easternegion. The equipment is comparatively higher on safety, comfort and accuracy to the regular

T scanners popularly in use.

r

C

Trivitron enters into JV with DiaSorin group

Trivitron Healthcare has collaborated with Italian immunodiagnostic firm DiaSorin S.p.A. The

51:49 joint venture (JV) between DiaSorin and Trivitron respectively has been etched with

the purpose of earning INR 1 bn within 2 years from the Indian market. Trivitron also plans

o manufacture some of Diasorin products from its Chennai located Trivitron’s Medicalt

Technology Park.

Trivitron is planning to strengthen its global reach through partnerships with companiesoperating in imaging and diagnostics space valued above INR 1 bn. The company's recent

arning of INR 4 bn PE fund from Fidelity Growth Partners India is being planned to be

artially used for making acquisitions in the US or Europe.

e

p

Healthcare Sector – Monthly Update

Sanofi to conduct clinical trial of dengue vaccine

Clinical trials of the world’s most effective vaccine candidate against dengue will soon be

conducted in India. The vaccination that has been devised by French pharmaceutical



company Sanofi Pasteur will be conducting the trials from Thailand to India to judge its

mpact over populations across countries. The drug controller general of India has requestedi

Sanofi to conduct phase II safety trials on adults followed by children.

he clinical trial results that are expected to be published by 2013, will finally aid in the

aunch of the vaccination by 2015.

T

l

L&T to sell off medical equipment business

Engineering company Larsen & Toubro (L&T) will be selling off its independent Mysore‐

ased medical equipment business to Mysore based Skanray Healthcare Pvt. Ltd. for anb

undisclosed amount.

The medical equipment business unit initiated in 1987 operated under L&T’s electrical and

automation (EA) unit and was into manufacturing of hospital medical equipments such as

patient monitors, ECG machines, syringe pumps, anesthesia delivery systems, ventilators,defibrillators, cardiac resuscitation systems, ultrasound and colour Doppler imaging, X‐ray

nd C‐Arm image intensifiers, hospital turnkey projects, telemedicine solutions and specialty

mbulances.

a

a

GSK to invest in its Indian consumer healthcare subsidiary

British drug maker GlaxoSmithKline (GSK) will be investing INR 52.15 bn to increase its

stake in Indian consumer healthcare subsidiary, GlaxoSmithKline Consumer Healthcare

(GSKCH). The investment will be made through a voluntary open offer. GSK that was initially

holding 43.2% stake in GSKCH, by purchasing 31.8% of the total outstanding shares at a

rice of INR 3,900 per share will as a result make GSK 75% stake owner of the public listedp

Indian company GSKCH.

The high investment buyback is an indication of the parent company’s confidence in

merging markets like India. The transaction will see GSKCH become a subsidiary of GSK

rom its initial position of being an associate company.

e

f

News Update

Regulatory CSIR soon to conduct clinical trial for tuberculosis

The Council for Scientific and Industrial Research (CSIR) will soon be conducting 1st phase of

clinical trial for tuberculosis in the next few months. The clinical trial will take place through

the Open Source Drug Discovery model which is a consortium led by CSIR in collaboration

with global drug companies aimed at solving complex problems associated with discovering

novel therapies for diseases. CSIR was allocated INR 0.5 bn during the 11th Five Year Plan




and it has further laid down a proposal of INR 6 bn for carrying out clinical trial in the 12 th

Five Year Plan.

In spite of the potential Indian tuberculosis market projects, there are currently no MNC drugmakers involved in drug discovery and its research. CSIR’s initiative in tuberculosis drug

discovery will bring relief to a large population that die in India every year.

News Update

Expansion Plans Intas enters agreement with Mayne Pharma

Ahmadabad based Intas Pharmaceuticals has recently etched a licensing deal with Australian

pharma company Mayne Pharma Corporation. Intas has agreed to supply 11 injectable

products for the Australian market. The products will be marketed in Australia under

ayne’s brand name and the company plans to file the products with the Therapeutic GoodsM

Administration (TGA) during 2013 calendar year.

Intas has been relying on companies with global reach to market its products internationally.

Prior to this deal, Intas has also signed agreements with Australia based Phosphagenics Ltd.

and UK based AstraZeneca for marketing of its products.

Miral introduces pharma products in Sierra Leone

Gurgaon based Miral Health Care Ltd. has made a move to distribute more than 30 medicinesand hospital consumables in Sierra Leone. The initiative has been undertaken solely for

improving the availability of pharma products in hospitals, clinics and pharmacies that faces

a severe dearth across the country. The products being distributed and marketed are World

ealth Organization (WHO) certified as well as registered with the Pharmacy Board of SierraH

Leone.

Miral has been focusing at distribution of drugs for the most common diseases like anemia of

ll cases, typhoid, fever, headache and general body pain along with treatment of feverish

ondition, cold symptoms, toothache, headaches and general body pain.

a

c

Spherix

and

Fullife

partners

to

popularize

D-

tagatose

Bethesda (in USA) located Spherix Incorporated and Mumbai based Fullife Healthcare Pvt.

Ltd. has entered into a partnership that seals a supply and license agreement for the use of D‐

tagatose in India. Fullife has been granted the exclusive right for use of nutraceutical

product’s clinical data and proprietary know‐how to support marketing and dosing of D‐

agatose in India by Spherix. By the agreement, Fullife will pay a fixed royalty on gross sales

o Spherix for D‐tagatose that will be used as supplement in food or cosmetic products.

t

t




T

d

he product being an adaptable compound can be formulated in several ways to help

iabetic and patients with metabolic syndrome cope with their disorders.

Cipla plans

majority

stake

holding

in

Cipla

Medpro

Mumbai based Cipla Ltd. is in plans to acquire a majority 51% stake in Cipla Medpro South

frica Ltd., Cipla’s distribution partner of South Africa along with a few other neighboringA

markets. Cipla will be investing close to INR 12.10 bn for the transaction.

Medpro operates in 2 divisions – Cape Town based Medpro that distributes a range of

chronic ailments and OTC medications. The other being, Durban based Cipla Medpro

Manufacturing which is the 1st international PIC/S‐compliant pharmaceutical manufacturing

acilities of South Africa. The manufacturing division is into production of selective products

nd also offers contract manufacturing solutions to local and multinational companies.

f

a

Industry Expert Speak

Trivitron enters into JV with Diasorin group - G S K Velu, Managing Director of Trivitron Group “Diasorin has been doing INR 2 bn business in India and the association with Trivitron will

help it scale its distribution network and garner INR 1 bn in 2 years. Immunoassaying, which

accounts for 40% of the total INR 25 bn diagnostic market in the country, is dominated by

ulti‐national companies like Abbots, Siemens and Rosch. The market for immunoassaying

as been growing faster at 25% than the entire diagnostics market.”

m

h

GSK to invest in its Indian consumer healthcare - David Redfern, Chief Strategy Officer, GSK "GSK Consumer Healthcare is a well established business in India and its leading product,

Horlicks, is an iconic household brand. This transaction represents a further step in GSK's

trategy to invest in the world's fastest growing markets and, we believe, offers a liquidity

pportunity at an attractive premium for existing shareholders,"

s

o

CSIR soon to conduct clinical trial for tuberculosis - Samir K Brahmachari, Director General, CSIR “With a vision to reduce the number substantially and eradicate TB completely by 2022, we

re taking various such initiatives on similar models like how the country achieved success in

radicating polio.”

a

e




Transaction Detail (Sep – Nov 2012)

Date Buyer Target Deal Size

(INR mn) % stake Deal Status

Type of

Transaction

26 vth No2012

Trivitron

Healthcare Pvt.Ltd.

Ani LabsystemsLtd.

1221.12 N.A. Completed Acquisition

22 vnd No2012

IncuCapital

Navigene

Genetic SciencePvt. Ltd.

N.A. N.A. Completed Private Equity

21st Nov2012

Cipla Ltd.Cipla Medpro

South Africa Ltd.12101.2 51% Completed Acquisition

8th Nov2012

Sun PharmaIndustries Ltd.

DUSA

Pharmaceuticals,Inc.

12.65 N.A. Planned Acquisition

3 t 1st Oc2012

GE EquityInternational

Mauritius

Syngene

(Biocon Ltd.

subsidiary)

International1250 7.69 Completed Private Equity

2 t 5th Oc

2012

Fidelity India

Capital

Trivitron

Healthcare4000 35‐40 Planned Private Equity

2 t 2nd Oc2012

Dr. Reddy'sLaboratories

OctoPlus N.V. 1930 100 Planned Acquisition

1 t 7th Oc

2012

Mylan

Laboratories

SMS

Pharmaceuticals’Vishakhapatnam

locatedmanufacturing

1730 N.A. Completed Acquisition

27th Sep2012

Norwest VenturePartners

ThyrocareTechnologies

1200 10 Completed Private Equity




12th Sep2012

Avigo CapitalPartners

Super ReligareLaboratories

2,916.79 N.A. Planned Private Equity

12th Sep2012

IndoUS

VenturePartners

Vyome

Biosciences Pvt Ltd.

185 N.A. Planned Private Equity

11th Sep2012

Norwest VenturePartners

ThyrocareTechnologies

Ltd1166.71 10 Planned Private Equity

5th Sep

2012

Norwest

Venture

Partners

NationWide

Primary

HealthcareServices Pvt. Ltd.

250 N.A. Completed Private Equity

Annual Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies FY ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 16,492.50 23,932.70 27,947.70 21,483.0

Blue Star Ltd. 25,026.2 25,249.7 29,536.8 27,888.5

Cadila Healthcare Ltd. 29,066.00 35,780.00 44,671.00 50,899.7

Cipla Ltd. 52,876.20 56,704.00 63,850.70 68,477.0

Dabur India Ltd. 28,122.40 33,958.00 40,817.40 52,832.0

Dr. Reddy’s Laboratories

(DRL)69,441.00 70,277.00 74,693.00 96,737.4

GlaxosmithKline

Consumer HealthcareLtd.

19,757.6 23,693.3 27,688.6 28,857.3

Glenmark

Pharmaceuticals Ltd.21,241.20 25,291.30 29,490.70 40,206.4

Jubilant life Sciences Ltd. 35,491.00 38,047.80 34,484.40 42,539.5

Lupin Ltd. 38,508.30 48,318.10 57,851.90 70,829.1




Nestle India Ltd. 51,395.5 62,609.4 74,994.6 77,409.0

Opto Circuits (India) Ltd. 8,185.197 10,775.826 15,855.631 23,568.543

Piramal Healthcare Ltd. 32,478.20 36,276.30 25,157.70 20,838.3

Ranbaxy Laboratories

Ltd.75,970.40 89,607.70 101,614.1 117,153.2

Siemens India Ltd. 93,070.2 96,272.4 119,718.1 124,657.9

Strides Arcolab Ltd. 13,101.6 16,958.4 25,245.2 25,645.1

Sun Pharmaceuticals

Industries Ltd.42,723.00 38,086.30 57,214.30 80,056.6

Torrent Pharmaceuticals

Ltd.

16,306.60 19,160.40 22,264.80 26,959.2

Wockhardt Ltd. 3,6294.4* 36,477.60 37,633.50 46,138.0

Annual Financial Results – Income (INR mn) - Major Healthcare

Companies

Companies F Y ’09 FY ’10 FY ’11 FY’ 12

Biocon Ltd. 931.2 2,932.40 3,675.20 3,384.0

Blue Star Ltd. 1,802.9 2,114.9 1,609.6 ‐1,051.0

Cadila Healthcare Ltd. 3,031.00 5,051.00 7,110.00 6,525.9

Cipla Ltd. 7,710.20 10,825.90 9,895.70 11,442.4

Dabur India Ltd. 3,905.00 5,010.80 5,685.70 6,449.0


(DRL) ‐5,168.00 1,068.00 11,040.00 14,262.1

GlaxoSmithKline Consumer

Healthcare Ltd.2,327.8 2,998.5 3,552.1 3,765.6

Glenmark Pharmaceuticals

Ltd.1,916.60 3,244.70 4,532.10 4,603.5




Jubilant life Sciences Ltd. 2,831.80 4,214.60 2,297.20 145.6

Lupin Ltd. 5,015.40 6,816.30 8,625.50 8,676.5

Nestle India Ltd. 6,550.0 8,186.6 9,615.5 9,815.7


Piramal Healthcare Ltd. 3,162.50 4,819.00 128,833.60 1,115.0

Ranbaxy Laboratories Ltd. 2,964.90 14,967.50 ‐28,997.3 ‐19,573.5

Siemens India Ltd. 7,046.0 7,577.7 8,677.5 7,300.6


Sun Pharmaceuticals

Industries Ltd.18,177.30 13,510.80 18,160.60 25,872.5

Torrent Pharmaceuticals Ltd. 1,843.70 2,312.00 2,701.70 2,840.4

Wockhardt Ltd. ‐4,355.4* ‐9,804.20 905.2 3,427.1

Quarterly Financial Results – Revenue (INR mn) – Major Healthcare

Companies Companies

Oct -Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Jul-Sep

2012

Biocon Ltd. 5,171.90 5,892.2 5,770.0 5,924.0

Blue Star Ltd. 5,896.9 N.A. N.A. N.A.

Cadila Healthcare Ltd. 13,524.60 14 .9,633 15 .0,161 15 .0,125

Cipla Ltd. 17,580.00 N.A N.A. N.A.




Dabur India Ltd. 14,526.80 13,858.3 14,620.0 15,226.0


(DRL)27,692.00 26,584.0 25,406.0 28,808.5

GlaxoSmithKline ConsumerHealthcare Ltd.

6,854.0 8,608.7 7,869.6 8,275.4

Glenmark Pharmaceuticals

Ltd.10,310.90 10,751.2 10,404.1 12,551.9

Jubilant life Sciences Ltd. 10,871.70 12,235.9 12,358.9 12,197.3

Lupin Ltd. 17,917.0 20,063.7 22,191.5 22,392.6

Nestle India Ltd. 19,633.2 20,558.7 19,865.8 21,155.9


Piramal Enterprises Ltd. 5,518.30 8,858.0 7,102.9 8,285.8

Ranbaxy Laboratories Ltd. 37,923.1 36,954.0 31,740.6 26,513.9

Siemens India Ltd. 30,458.2 37 2601.43 33,082.4 32,693.6


Sun Pharmaceuticals

Industries Ltd.21,451.30 23,299.3 26,581.4 26,572.4

Torrent Pharmaceuticals Ltd. 6,965.9 6,686.8 7,356.0 7,471.7

Wockhardt Ltd. 12,086.70 12,413.90 14,258.2 13,474.4

Companies Oct

-Dec

2011

Jan-Mar

2012

Apr-Jun

2012

Jul-Sep

2012

Biocon Ltd. 848.50 978.0 790.0 896.5

Blue Star Ltd. (327.6) N.A. N.A. N.A.

Cadila Healthcare Ltd. 1,492.10 1,708.8 1,947.9 951.4

Quarterly Financial Results – Income (INR mn) - Major Healthcare

Com anies




Cipla Ltd. 2,699.10 N.A. N.A. N.A.

Dabur India Ltd. 1,728.20 1,705.1 1,494.0 2,023.7

Dr. Reddy’s Laboratories(DRL)

5,130.0 3,427.0 3,360.0 4,074.4

GlaxoSmithKline Consumer

Healthcare Ltd.591.0 1,319.7 1,066.0 1,285.5

Glenmark PharmaceuticalsLtd.

461.20 1,482.7 782.8 1,567.5

Jubilant life Sciences Ltd. ‐783.90 ‐635.3 50.1 1,520.0

Lupin Ltd. 2,350.60 1,556.4 2,803.9 2,904.6

Nestle India 2,308.30 2,757.3 2,459.7 2,673.1


Piramal Enterprises Ltd. 85.2 ‐386.8 40.8 (920.2)

Ranbaxy Laboratories Ltd. ‐29,827.7 12,467.6 ‐5,857.3 7,541.7

Siemens India Ltd. 1,873.6 3,040.0 (157.8) (557.7)

Strides Arcolab Ltd 684.1 6,420.7 904.8 524.9

Sun Pharmaceuticals

Industries Ltd. 6,683.0 8202.1 7,955.5 3,196.4

Torrent Pharmaceuticals Ltd 831.8 ‐16.5 1,018.5 1,072.5

Wockhardt Ltd. 2,128.10 ‐1,916.4 3,779.7 4,535.5

* denotes a change in financial year




Events Calendar

1st International Fellowship on Health

Techn loo gy Assessment

ate: 9

D th –16th Dec, 2012Venue: Am

A

rita Institute of Medical Sciences at

iencesmriteshwari Hall

dical ScOrganizer: Amrita Institute Of MeWebsite: http://www.aimshospital.org/ Contact Person: Dr. Sanjeev SinghContact No.: +91‐484‐6681234

Biofest -2012 International Bio Conference and

Event

Date: 12th‐13th Dec, 2012Venue: Leonia International Centre for

Exhibitions & Conventions, HyderabadOrganize ferences &r: Bright International Con

Event Website:

s Organizationhttp://www.brightice.org

Contact Person: Hari KrishnaContact No.: +91‐40‐64540825

Research on India (ROI) is a leading source for market research on various sectors in India

hat offers premium research content from worldwide publishers of market researcht

reports.

Contact us:

mW: https://www.researchonindia.co

; International: +91 (33) 4027 6214/5T

E

: India (Toll Free): 1800 102 1133

: [email protected]

Connect with Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document.


http://www.brightice.org/










http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

https://twitter.com/ResearchOnIndia

http://www.facebook.com/researchonindia


healthcare sector in india monthly update november 2012

Documents